Androgen Deprivation Therapy Market Size (2024 - 2029)

Androgen Deprivation Therapy Market Analysis

The Androgen Deprivation Therapy Market size is estimated at USD 6.10 billion in 2024, and is expected to reach USD 8.10 billion by 2029, growing at a CAGR of 5.80% during the forecast period (2024-2029).

The key factors propelling the market growth are the rising burden of prostate cancer, increasing research and development activities, advancements in treatment technology for effective treatment of prostate cancer, rising product approvals, and strategic initiatives adopted by key market players.

The growing burden of prostate cancer is expected to increase demand for effective treatment with androgen deprivation therapy, thereby boosting the market growth. For instance, according to the Canadian Cancer Society Report 2024, prostate cancer is set to account for one in five new cancer cases in Canadian males, with an estimated 27,900 new diagnoses expected in 2024. Thus, the high incidence of prostate cancer is expected to contribute to the segment growth over the forecast period.

Strategies such as partnerships, distribution agreements, mergers, and acquisitions adopted by key market players are expected to boost market growth. For instance, in May 2022, Myovant Sciences and Accord Healthcare Ltd entered an exclusive license agreement for Accord to commercialize Relugolix for the treatment of advanced hormone-sensitive prostate cancer under the trade name ORGOVYX (Relugolix, 120 mg) in the European Economic Area, the United Kingdom, Switzerland, and Turkey. Such partnerships will expand the accessibility of ORGOVYX across geographies, thereby leading to lucrative market growth.

Furthermore, achieving milestones in the drug development cycle will also fuel market growth. For instance, in May 2022, Bayer reported that the United States Food and Drug Administration (FDA) accepted a supplemental New Drug Application (NDA) and granted Priority Review for the oral androgen receptor inhibitor (ARi) darolutamide in combination with docetaxel for the treatment of metastatic hormone-sensitive prostate cancer (HSBC). Similarly, in March 2023, the European Commission approved Nubeqa (darolutamide), an oral androgen receptor inhibitor (ARi), plus androgen deprivation therapy (ADT) in combination with docetaxel, for the treatment of patients with metastatic hormone-sensitive prostate cancer (mHSPC).

Therefore, owing to the factors above, the market is expected to grow significantly during the study period. However, limited reimbursement policies and increasing side effects are expected to hinder the market growth during the study period.

Androgen Deprivation Therapy Industry Segmentation

As per the scope of the report, androgen deprivation therapy is hormone therapy for prostate cancer in males by suppressing excess androgen. Androgen is a sex hormone produced in the testes and adrenalin glands in the form of testosterone and dihydrotestosterone.

The androgen deprivation therapy market is segmented by therapeutic class, route of administration, and geography. By therapeutic class, the market is segmented as luteinizing hormone-releasing hormone (LHRH) agonists and antiandrogens. By route of administration, the market is segmented as injectable and oral. By geography, the market is segmented as North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The market report also covers the estimated market sizes and trends for 17 countries across major regions globally. The report offers the value (in USD) for the above segments.